MED1 in cancer: a context-dependent transcriptional regulator

Abstract

Mediator complex subunit 1 (MED1; also known as TRAP220 and PBP) is a non-DNA-binding transcriptional co-regulator whose apparently opposing roles in cancer cannot be inferred from expression level alone. This review advances an evidence-weighted, locus- and complex-centered framework to reconcile the MED1 paradox. We distinguish causal genetic and mechanistic data from clinicopathological associations and propose that MED1 output is determined by lineage-specific transcription-factor recruitment, genomic occupancy, signaling-dependent modification, chromatin state, and cellular context. Direct evidence supports MED1-dependent oncogenic transcription in estrogen receptor-driven breast cancer, androgen receptor-driven prostate cancer, E2A-PBX1-positive B-cell acute lymphoblastic leukemia, and hepatocyte tumor models. In contrast, MED1 loss promotes invasive behavior in defined non-small-cell lung cancer and melanoma models, whereas findings in colorectal and bladder cancer remain largely correlative. We further evaluate MED1 enrichment at super-enhancer-associated assemblies and transcriptional condensates, emphasizing that enrichment does not by itself establish structural or functional necessity. Finally, we assess indirect pharmacologic strategies and RNA-based suppression, noting the absence of a clinically validated MED1-selective inhibitor or degrader. By shifting the focus from pan-cancer expression to partner-, locus-, and model-specific dependency, this framework defines testable biomarkers and therapeutic hypotheses for selectively targeting oncogenic MED1 complexes while preserving physiological MED1 functions.